SK14982000A3 - Spôsob inhibície mrp1 - Google Patents

Spôsob inhibície mrp1 Download PDF

Info

Publication number
SK14982000A3
SK14982000A3 SK1498-2000A SK14982000A SK14982000A3 SK 14982000 A3 SK14982000 A3 SK 14982000A3 SK 14982000 A SK14982000 A SK 14982000A SK 14982000 A3 SK14982000 A3 SK 14982000A3
Authority
SK
Slovakia
Prior art keywords
methyl
compound
dihydro
isoxazolo
substituted
Prior art date
Application number
SK1498-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Joseph Michael Gruber
Bryan Hurst Norman
Julian Stanley Kroin
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK14982000A3 publication Critical patent/SK14982000A3/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Control Of The Air-Fuel Ratio Of Carburetors (AREA)
  • Magnetically Actuated Valves (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1498-2000A 1998-04-08 1999-04-07 Spôsob inhibície mrp1 SK14982000A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8108098P 1998-04-08 1998-04-08
PCT/US1999/007613 WO1999051228A1 (en) 1998-04-08 1999-04-07 Methods for inhibiting mrp1

Publications (1)

Publication Number Publication Date
SK14982000A3 true SK14982000A3 (sk) 2001-05-10

Family

ID=22161981

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1498-2000A SK14982000A3 (sk) 1998-04-08 1999-04-07 Spôsob inhibície mrp1

Country Status (18)

Country Link
US (1) US6369070B1 (id)
EP (1) EP1067928A4 (id)
JP (1) JP2002510625A (id)
KR (1) KR20010042471A (id)
CN (1) CN1304306A (id)
AU (1) AU3476999A (id)
BR (1) BR9910112A (id)
CA (1) CA2327617A1 (id)
EA (1) EA200001034A1 (id)
HR (1) HRP20000646A2 (id)
HU (1) HUP0101508A3 (id)
ID (1) ID27364A (id)
IL (1) IL138389A0 (id)
NO (1) NO20005023L (id)
PL (1) PL343313A1 (id)
SK (1) SK14982000A3 (id)
TR (1) TR200002851T2 (id)
WO (1) WO1999051228A1 (id)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60025744D1 (de) * 1999-10-07 2006-04-13 Lilly Co Eli Kondensierte dihydrochinolinon-derivate zur hemmung von mrp1
US6743794B2 (en) 1999-12-22 2004-06-01 Eli Lilly And Company Methods and compounds for inhibiting MRP1
WO2001046199A1 (en) * 1999-12-22 2001-06-28 Eli Lilly And Company Methods and compounds for inhibiting mrp1
WO2001096346A1 (en) * 2000-06-14 2001-12-20 Eli Lilly And Company Tricyclic compounds as mrp1-inhibitors
WO2002024705A1 (en) * 2000-09-22 2002-03-28 Eli Lilly And Company Stereoselective process for preparing cyclohexyl amine derivatives
JP2004529919A (ja) * 2001-04-09 2004-09-30 イーライ・リリー・アンド・カンパニー Mrp1を阻害するための化合物および方法
US7101891B2 (en) 2001-04-09 2006-09-05 Eli Lilly And Company Compounds and pharmaceutical compositions for inhibiting MRP1
CA2442530A1 (en) * 2001-04-09 2002-10-17 Rosanne Bonjouklian Compounds and methods for inhibiting mrp1
EP1684762A4 (en) * 2003-11-13 2009-06-17 Ambit Biosciences Corp UREA DERIVATIVES AS MODULATORS OF KINASE
WO2005113519A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588731A (en) * 1985-06-21 1986-05-13 Roussel Uclaf Derivatives of isoxazolo[4,5-c]quinoline(2H)-3-one and method of preparation and use as anxiolytic agents
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity

Also Published As

Publication number Publication date
TR200002851T2 (tr) 2000-12-21
HUP0101508A2 (hu) 2001-10-28
EP1067928A1 (en) 2001-01-17
US6369070B1 (en) 2002-04-09
BR9910112A (pt) 2000-12-26
HRP20000646A2 (en) 2001-06-30
AU3476999A (en) 1999-10-25
CA2327617A1 (en) 1999-10-14
JP2002510625A (ja) 2002-04-09
NO20005023D0 (no) 2000-10-05
HUP0101508A3 (en) 2002-04-29
IL138389A0 (en) 2001-10-31
PL343313A1 (en) 2001-08-13
CN1304306A (zh) 2001-07-18
WO1999051228A1 (en) 1999-10-14
EP1067928A4 (en) 2001-11-14
NO20005023L (no) 2000-12-05
ID27364A (id) 2001-04-05
KR20010042471A (ko) 2001-05-25
EA200001034A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
CN102822171B (zh) 作为自分泌运动因子抑制剂的苯并萘啶胺类
US6670373B1 (en) Compounds and method for inhibiting MRP1
TW200307539A (en) Cycloalkyl inhibitors of potassium channel function
SK14982000A3 (sk) Spôsob inhibície mrp1
AU715493B2 (en) Selective beta 3 adrenergic agonists
WO2007080109A1 (en) Substituded benzyloxy-phenylmethylurea derivatives
US20090149488A1 (en) Tetrahydroprotoberberine Compounds, the Synthetic Method and the Use Thereof
CN103980252A (zh) 制备含1,2,4-三氮唑的吡唑类席夫碱治疗肿瘤的药物
PL231063B1 (pl) Pochodne 1-(podstawionej sulfonylo)-2-aminoimidazoliny jako środki przeciwnowotworowe
US6673809B2 (en) Tricyclic compounds as MRP1-inhibitors
BRPI0620090A2 (pt) diazepinonas
US6221876B1 (en) Methods for inhibiting MRP1
JP2002510624A (ja) Mrp1の阻害方法
EP3221307A1 (en) Novel 1,3,5 -triazine based pi3k inhibitors as anticancer agents and a process for the preparation thereof
JP2004511486A (ja) デルタ−オピオイドアゴニストおよびアンタゴニストとしてのモルフィノイド誘導体
US6686376B2 (en) Methods and compounds for inhibiting MRP1
CZ20003687A3 (cs) Způsoby inhibice MRP1
CA2758610A1 (en) Process 738
WO2022022388A1 (zh) 一种地佐辛衍生物晶型a及其制备方法和应用
MXPA00009655A (en) Methods for inhibiting mrp1
Class et al. Patent application title: INHIBITORS OF MTOR-DEPTOR INTERACTIONS AND METHODS OF USE THEREOF
CZ20003688A3 (cs) Způsob inhibice MRP1
CN110627777A (zh) 一种苯并噻吩化合物的马来酸盐、其结晶形式及其用途
MXPA00009825A (en) Methods for inhibiting mrp1
CZ20003689A3 (cs) Způsob inhibice MRP1